Status: Recruiting
Combination Immunotherapy Targeting Sarcomas
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 1-75Biological sex: AllType: InterventionalSponsor: Shenzhen Geno-Immune Medical InstituteUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients; [+12]
The disease is progressing rapidly; [+15]